Why does GM1 induce a potent beneficial response to experimental Chagas disease?
- PMID: 19794814
- PMCID: PMC2707790
- DOI: 10.2976/1.3067922
Why does GM1 induce a potent beneficial response to experimental Chagas disease?
Abstract
Being one of the world's neglected diseases, Chagas has neither a vaccine nor a satisfactory therapy. Inoculation of murine models with the ganglioside GM1 has shown a strikingly nonlinear effect, leading to a strong decrease in parasite load at low doses but reverting to a load increase at high doses. Cardiocyte destruction concomitant with the disease is also significantly reduced by a moderate application of GM1. A mathematical model for the interaction between the parasite and the immune system is shown to explain these effects and is used to predict an optimal dosage that maximizes parasite removal with minimal cardiocyte destruction.
Figures



Similar articles
-
GM1 ganglioside induced myocardial restoration and survival of mice with experimental Chagas' disease.Acta Trop. 1999 Oct 15;73(3):295-302. doi: 10.1016/s0001-706x(99)00030-3. Acta Trop. 1999. PMID: 10546847
-
Immunomodulatory and anti-fibrotic effects of ganglioside therapy on the cardiac chronic form of experimental Trypanosoma cruzi infection.Int Immunopharmacol. 2011 Aug;11(8):1024-31. doi: 10.1016/j.intimp.2011.02.022. Epub 2011 Mar 1. Int Immunopharmacol. 2011. PMID: 21371583
-
The Case for the Development of a Chagas Disease Vaccine: Why? How? When?Trop Med Infect Dis. 2021 Jan 26;6(1):16. doi: 10.3390/tropicalmed6010016. Trop Med Infect Dis. 2021. PMID: 33530605 Free PMC article. Review.
-
Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion.Neuropharmacology. 1995 May;34(5):489-93. doi: 10.1016/0028-3908(95)00015-x. Neuropharmacology. 1995. PMID: 7566482
-
Gangliosides, α-Synuclein, and Parkinson's Disease.Prog Mol Biol Transl Sci. 2018;156:435-454. doi: 10.1016/bs.pmbts.2017.12.009. Epub 2018 Feb 24. Prog Mol Biol Transl Sci. 2018. PMID: 29747823 Review.
References
-
- Andrade, A LSS, et al. (1996). “Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.” Lancet LANCAO 348, 1407–1413. - PubMed
-
- Brener, Z (1980). “Immunity to Trypanosoma cruzi.” Adv. Parasitol. ZZZZZZ 18, 247–292. - PubMed
-
- Bronia, D H, Aguerri, A M, and Bertetto, S T (1986). “Trypanosoma cruzi: changes in lipid composition during aging in culture.” Exp. Parasitol. ZZZZZZ 61, 151–159. - PubMed
LinkOut - more resources
Full Text Sources